Skip to main content
60°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
8.410
+0.220 (+2.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
April 17, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
April 17, 2024
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 17, 2024
Via
Benzinga
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
April 17, 2024
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 17, 2024
Via
Benzinga
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
March 26, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
February 28, 2024
Via
Benzinga
Earnings Scheduled For February 14, 2024
February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.
Via
Benzinga
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
April 17, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
April 17, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 11, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
The Latest Analyst Ratings for Sage Therapeutics
December 12, 2023
Via
Benzinga
Analyst Ratings for Sage Therapeutics
November 08, 2023
Via
Benzinga
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
February 15, 2024
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday.
Via
Benzinga
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
February 14, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
January 31, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Why Sage Therapeutics Stock Sank Today
November 07, 2023
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
Via
The Motley Fool
Sage Therapeutics Announces Changes to Board of Directors
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
January 02, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics to Present at Upcoming November Investor Conferences
November 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
November 07, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 24, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
October 18, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.